DTAB Charter 2004
PURPOSE
The Substance Abuse and Mental
Health Services Administration seeks to improve the quality of services for
forensic workplace urine drug testing, assess the science and technology used
in drug analyses, improve the quality of related laboratory services and
systems for drug testing, generate standards for laboratory certification for
Federal workplace drug testing programs, and guide national policy in these
areas by the establishment of the Drug Testing Advisory Board.
AUTHORITY
42 U.S.C. 290aa(h), Section 501 of
the Public Health Service Act, as amended. The Drug Testing Advisory Board is
governed by the provisions of Public Law 92-463, as amended (5 U.S.C. Appendix
2), which set forth standards for the formation and use of advisory committees.
FUNCTION
The Drug Testing Advisory Board
shall advise the Administrator, Substance Abuse and Mental Health Services
Administration, based on an ongoing review of the direction, scope, balance,
and emphasis of the Agency's drug testing activities and the drug testing
laboratory certification program.
The Board shall review the
Agency's program for national laboratory certification for Federal workplace
drug testing programs as required by Public Law 100-71 and as described in the
Mandatory Guidelines for Federal Workplace Drug Testing Programs. It shall
recommend areas for emphasis or de-emphasis, new or changed directions, and
mechanisms or approaches for implementing recommendations. Periodically, the
Board shall review specific science areas on new drugs of abuse and the methods
necessary to detect their presence.
STRUCTURE
The Drug Testing Advisory Board
shall consist of the Director, Division of Workplace Programs, Center for
Substance Abuse Prevention, as Chair, and 10 members selected by the
Administrator, Substance Abuse and Mental Health Services Administration. The
10 members appointed to the Board shall be recognized as experts in either
analytical forensic toxicology, in specimen collection procedures for regulated
drug testing programs, or in interpreting drug testing results. The individuals
appointed should represent a variety of disciplines related to forensic drug
testing such as experience in a forensic drug testing laboratory, related
academic research, toxicological research, the Medical Review Officer
community, or technical expertise from other government agencies involved with
drug testing issues, including military drug testing programs.
Members shall be invited to serve
for overlapping four year terms; terms are contingent upon the continuation of
the Board.
Management and support services
shall be provided by the Division of Workplace Programs, Center for Substance
Abuse Prevention, Substance Abuse and Mental Health Services Administration.
MEETINGS
Meetings shall be held
approximately four times a year at the call of the Chair, who shall also
approve the agenda. A quorum for the conduct of business shall be six members.
A government official shall be present at all meetings.
Meetings shall be open to the
public except as determined otherwise by the Secretary or other official to
whom the authority has been delegated; notice of all meetings shall be given to
the public.
Meetings shall be conducted and
records of the proceedings kept as required by applicable laws and Departmental
regulations.
COMPENSATION
Members who are not full time
Federal employees shall be paid at the rate of $200 per day, plus per diem and
travel expenses in accordance with Standard Government Travel Regulations.
Federal employees shall not receive compensation for service on the Board, but
will receive per diem and travel expenses in accordance with Standard
Government Travel Regulations.
ANNUAL COST ESTIMATE
The estimated annual cost for
operating the Board, including compensation and travel expenses for members,
but excluding staff support, is $75,632. The estimate of annual person years of
staff support is 0.60, at an estimated annual cost of $58,519.
REPORTS
In the event a portion of a
meeting is closed to the public, a report shall be prepared which shall
contain, at a minimum, a list of members and their business addresses, the
Board's functions, dates and places of meetings, and a summary of the Board's
activities and recommendations made during the fiscal year. A copy of the
report shall be provided to the Department Committee Management Officer.
DURATION
Unless renewed by appropriate
action prior to expiration, the Drug Testing Advisory Board will terminate on
June 15, 2006.
APPROVED:
June 15, 2004
/signed/
__________________________
________________________________
Date
Date Charles G. Curie, M.A.,
A.C.S.W.
Administrator
|
